Advanced Filters
noise

One or multiple investigational sites, Spain Clinical Trials

A listing of One or multiple investigational sites, Spain clinical trials actively recruiting patients volunteers.

Found 64,920 clinical trials

Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.

The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.

18 - 75 years of age All Phase 3
T Tao Sun

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

A placebo-controlled superiority design was used to evaluate the efficacy of 60 mg/ day or 120 mg/ day of Buagafuran capsules in the treatment of GAD

18 - 65 years of age All Phase 3
A Ana Belén Peinado Lozano

Assessment of Training Status

The goal of this cross-over study is to evaluate the physiological response to exercise and body composition according to training status in participants with a wide spectrum of fitness states. The main questions it aims to answer are: Which are the physiological differences across participants with different training status? Which …

years of age All Phase N/A

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study …

18 years of age All Phase 3

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children < 2 years of age genetically diagnosed with …

3 - 24 years of age All Phase 4
S SARTELET Lydie

Evaluation of the Safety Plan to Prevent Suicidal Reiteration

Each year, suicide is the cause of 8,580 deaths in France, it is the second leading cause of death among 15-24 year olds. People who have made a first suicide attempt are identified as being at greater risk of repeating a suicidal gesture, particularly in the first month following the …

18 - 65 years of age All Phase N/A

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy of guselkumab in pediatric participants with moderately to severely active ulcerative colitis at the end of maintenance therapy among participants who were induction responders.

2 - 17 years of age All Phase 3

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.

1 - 18 years of age All Phase 3

Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

The goal of this clinical biomarker validation trial is to test the effect of a predictive biomarker panel to human albumin infusions in patients with liver cirrhosis and ascites. The main questions it aims to answer are: If the predictive biomarker panel can identify patients who are likely to benefit …

18 years of age All Phase 3
M Michelle R vanDellen, PhD

Dyadic Financial Incentive Treatments for Dual Smoker Couples

Smokers partnered with other smokers (i.e., dual-smoker couples) represent ~2/3 of all smokers. Dual-smoker couples (DSCs) are less likely to try to quit smoking and more likely to relapse during a quit attempt, reducing overall smoking cessation rates and representing a high-risk clinical population. Despite their high prevalence and risk …

18 years of age All Phase N/A

Simplify language using AI